Zevra Therapeutics Inc. (ZVRA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $540.30M
Last updated: Nov 17, 2026 at 11:06 AM ET
Zevra Therapeutics Inc. (ZVRA) Earnings: Report Dates and Results
Zevra Therapeutics (ZVRA) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, Zevra Therapeutics reported EPS of $0.18, above the $0.14 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ZVRA has an expected report date of Mar 8, 2027.
ZVRA Earnings Call
The latest ZVRA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, ZVRA beat 18, missed 20 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $37.76M, up 44.9% from $26.06M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.18 | $0.14 | $0.13 - $0.21 | +28.57% | Beat | N/A | 3 | 2 up, 0 down | Nov 3, 2026 | $37.76M |
| Jun 30, 2026 | $0.25 | $0.08 | N/A | +212.50% | Beat | N/A | 3 | 2 up, 1 down | Aug 5, 2026 | $39.66M |
| Mar 31, 2026 | $0.18 | $0.08 | $0.01 - $0.18 | +125.00% | Beat | N/A | 8 | 0 up, 2 down | May 6, 2026 | $36.22M |
| Dec 31, 2025 | $0.19 | $0.05 | -$0.01 - $0.07 | +280.00% | Beat | N/A | 4 | 1 up, 0 down | Mar 9, 2026 | $34.13M |
| Sep 30, 2025 | -$0.01 | -$0.04 | -$0.04 - $0.01 | +75.00% | Beat | N/A | 4 | 4 up, 0 down | Nov 5, 2025 | $26.06M |
| Jun 30, 2025 | -$0.06 | $1.38 | -$0.12 - $2.64 | -104.35% | Miss | N/A | 8 | 2 up, 1 down | Aug 12, 2025 | $25.88M |
| Mar 31, 2025 | -$0.06 | -$0.18 | -$0.24 - -$0.12 | +66.67% | Beat | N/A | 7 | 3 up, 2 down | May 13, 2025 | $20.40M |
| Dec 31, 2024 | -$0.69 | -$0.40 | -$0.54 - -$0.29 | -73.11% | Miss | N/A | 7 | 1 up, 0 down | Mar 11, 2025 | $12.04M |
| Sep 30, 2024 | -$0.69 | -$0.41 | -$0.50 - -$0.36 | -68.29% | Miss | N/A | 8 | 0 up, 0 down | Nov 12, 2024 | $3.69M |
| Jun 30, 2024 | -$0.48 | -$0.44 | -$0.49 - -$0.31 | -9.09% | Miss | N/A | 5 | 1 up, 0 down | Aug 13, 2024 | $4.45M |
| Mar 31, 2024 | -$0.40 | -$0.48 | -$0.51 - -$0.42 | +16.67% | Beat | N/A | 5 | 1 up, 0 down | May 8, 2024 | $3.42M |
| Dec 31, 2023 | -$0.40 | -$0.27 | -$0.54 - -$0.04 | -48.15% | Miss | N/A | 6 | 1 up, 0 down | Mar 28, 2024 | $12.92M |
| Sep 30, 2023 | -$0.40 | -$0.30 | -$0.38 - -$0.25 | -33.33% | Miss | N/A | 4 | 0 up, 0 down | Nov 7, 2023 | $2.90M |
| Jun 30, 2023 | -$0.15 | -$0.34 | N/A | +55.88% | Beat | N/A | N/A | N/A | Aug 14, 2023 | $8.47M |
| Mar 31, 2023 | -$0.34 | -$0.23 | N/A | -47.83% | Miss | N/A | N/A | N/A | May 15, 2023 | $3.18M |
| Dec 31, 2022 | -$0.26 | -$0.17 | N/A | -52.94% | Miss | N/A | N/A | N/A | Mar 7, 2023 | $2.02M |
| Sep 30, 2022 | -$0.19 | -$0.10 | N/A | -90.00% | Miss | N/A | N/A | N/A | Nov 9, 2022 | $2.87M |
| Jun 30, 2022 | -$0.70 | -$0.14 | N/A | -400.00% | Miss | N/A | N/A | N/A | Aug 11, 2022 | $1.30M |
| Mar 31, 2022 | -$0.05 | -$0.05 | N/A | 0.00% | In line | N/A | N/A | N/A | May 12, 2022 | $3.96M |
| Dec 31, 2021 | -$0.08 | -$0.07 | N/A | -14.29% | Miss | N/A | N/A | N/A | Mar 30, 2022 | $2.58M |
| Sep 30, 2021 | -$0.05 | -$0.08 | N/A | +37.50% | Beat | N/A | N/A | N/A | Nov 10, 2021 | $1.97M |
| Jun 30, 2021 | -$0.40 | $0.23 | N/A | -273.91% | Miss | -350.0% | N/A | N/A | Aug 12, 2021 | $11.99M |
| Mar 31, 2021 | -$1.61 | -$0.17 | N/A | -847.06% | Miss | N/A | N/A | N/A | May 13, 2021 | $12.12M |
| Dec 31, 2020 | -$1.07 | -$0.64 | N/A | -67.19% | Miss | N/A | N/A | N/A | Mar 11, 2021 | $2.37M |
| Sep 30, 2020 | -$0.64 | -$0.80 | N/A | +20.00% | Beat | -166.7% | N/A | N/A | Oct 29, 2020 | $1.93M |
| Jun 30, 2020 | $0.16 | -$0.02 | N/A | +900.00% | Beat | N/A | N/A | N/A | Aug 12, 2020 | $6.91M |
| Mar 31, 2020 | -$1.92 | -$1.76 | N/A | -9.09% | Miss | N/A | N/A | N/A | May 12, 2020 | $2.09M |
| Dec 31, 2019 | -$0.16 | -$1.36 | N/A | +88.24% | Beat | N/A | N/A | N/A | Feb 28, 2020 | $1.38M |
| Sep 30, 2019 | $0.96 | -$4.48 | N/A | +121.43% | Beat | N/A | N/A | N/A | Nov 14, 2019 | $11.46M |
| Jun 30, 2019 | -$5.28 | -$6.80 | N/A | +22.35% | Beat | N/A | N/A | N/A | Aug 13, 2019 | N/A |
| Mar 31, 2019 | -$7.36 | -$7.36 | N/A | 0.00% | In line | N/A | N/A | N/A | May 14, 2019 | N/A |
| Dec 31, 2018 | -$3.20 | -$7.60 | N/A | +57.89% | Beat | N/A | N/A | N/A | Feb 28, 2019 | N/A |
| Sep 30, 2018 | -$13.41 | -$12.32 | N/A | -8.85% | Miss | N/A | N/A | N/A | Nov 8, 2018 | N/A |
| Jun 30, 2018 | -$10.40 | -$15.42 | N/A | +32.56% | Beat | N/A | N/A | N/A | Aug 9, 2018 | N/A |
| Mar 31, 2018 | -$28.32 | -$11.04 | N/A | -156.52% | Miss | N/A | N/A | N/A | May 10, 2018 | N/A |
| Dec 31, 2017 | -$11.52 | -$10.96 | N/A | -5.11% | Miss | N/A | N/A | N/A | Mar 29, 2018 | N/A |
| Sep 30, 2017 | -$10.88 | -$10.76 | N/A | -1.12% | Miss | N/A | N/A | N/A | Nov 9, 2017 | N/A |
| Jun 30, 2017 | -$7.04 | -$10.08 | N/A | +30.16% | Beat | N/A | N/A | N/A | Aug 10, 2017 | N/A |
| Mar 31, 2017 | -$13.44 | -$10.24 | N/A | -31.25% | Miss | N/A | N/A | N/A | May 10, 2017 | N/A |
| Dec 31, 2016 | -$10.88 | -$11.15 | N/A | +2.42% | Beat | N/A | N/A | N/A | Mar 9, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.06, a profit after a loss of $2.26 per share the year before. It was -$34.72 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.06 | N/A |
| Dec 31, 2024 | -$2.26 | N/A |
| Dec 31, 2023 | -$1.29 | N/A |
| Dec 31, 2022 | -$1.20 | N/A |
| Dec 31, 2021 | -$2.14 | N/A |
| Dec 31, 2020 | -$3.47 | N/A |
| Dec 31, 2019 | -$11.84 | N/A |
| Dec 31, 2018 | -$55.33 | N/A |
| Dec 31, 2017 | -$42.88 | N/A |
| Dec 31, 2016 | -$34.72 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,900 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,895 | 12 | |
| 2026Q1 | Mar 31, 2026 | 4,962 | 11 | |
| 2025Q4 | Dec 31, 2025 | 6,785 | 11 | |
| 2025Q3 | Sep 30, 2025 | 6,446 | 12 | |
| 2025Q2 | Jun 30, 2025 | 4,708 | 12 | |
| 2025Q1 | Mar 31, 2025 | 5,843 | 9 | |
| 2024Q4 | Dec 31, 2024 | 7,019 | 12 | |
| 2024Q3 | Sep 30, 2024 | 6,489 | 11 |
2026Q3 Earnings Call
Opening remarks
Nichol Ochsner Vice President of Investor Relations and Corporate Communications Thank you, and welcome to those who are joining us. Today, we will provide an overview of our recent accomplishments, followed by a review of our third quarter 2026 financial results. I encourage you to read our financial results news release, which was distributed this afternoon and is available in the Investors section of our website. Before we begin the call, please note that certain information shared today will include forward-looking statements. Actual results may differ materially from those stated or implied by any forward-looking statements due to risks and uncertainties associated with Zevra's business. Forward-looking statements are not promises or guarantees and are inherently subject to risks, uncertainties, and other important factors that may lead to actual results differing materially from the projections made. They should be evaluated together with the Risk Factors section in our most recent quarterly report on Form 10-Q, our annual report on Form 10-K, and our other filings with the SEC. I'm pleased to welcome Zevra's management team members participating in today's call: Neil McFarlane, Zevra's President and Chief Executive Officer; Joshua Schafer, our Chief Commercial Officer; and Justin Renz, our Chief Financial Officer. Now it's my pleasure to hand the call over to Neil.
Neil McFarlane President and Chief Executive Officer Thank you, Nichol, and welcome to everyone joining our quarterly call this afternoon. Zevra is a purpose-driven company, redefining what is possible and bringing life-changing therapies to people living with rare diseases. In rare disease, the path is complex. The needs are urgent, and the responsibility is significant. The people and families behind these needs are at the heart of what we do every day. Progress with the U.S. launch of MIPLYFFA, the first approved therapy for Niemann-Pick disease Type C, or NPC, reflects the disciplined execution of our strategic plan and the determination, expertise, and commitment of our people. Together, we are building a trusted company with the capabilities and resolve to make a lasting difference. I'm pleased to share that total net revenue for the third quarter was $37.8 million, an increase of 45% compared to the third quarter of 2025, and net U.S. product revenue for MIPLYFFA was $34 million. What we're seeing in the market suggests that it may be just the beginning, particularly as we strengthen our understanding of the NPC community in the United States, where an estimated 900 people are living with NPC, of whom 300 to 350 have been diagnosed. These estimates are derived from a study published in 2021, prior to any approved treatment for NPC. In the third quarter, we received 13 prescription enrollment forms, bringing the cumulative total since launch to 197.
Frequently Asked Questions About ZVRA
When is Zevra Therapeutics's next earnings date?
Zevra Therapeutics's next earnings report is expected for Mar 8, 2027.
Did ZVRA beat earnings estimates last quarter?
Yes. Zevra Therapeutics reported EPS of $0.18 for the quarter ended Sep 30, 2026, above the $0.14 estimate, a 28.57% surprise.
What EPS do analysts expect from ZVRA next quarter?
The consensus EPS estimate for Zevra Therapeutics for the quarter ending Dec 31, 2026 is $0.19 from 11 analysts, with estimates from $0.13 to $0.25.
How often does ZVRA beat earnings estimates?
Zevra Therapeutics beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +76.29%.
ZVRA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors